Marksans Pharma (BOM:524404) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


BOM:524404 Marksans Pharma Ltd BOM:524404
85 GF Score
Price ₹267.05
GF Value ₹227.84
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Marksans Pharma Research & Development?

Marksans Pharma BOM:524404 -0.61% 85 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:524404 with a GF Score™ of 85/100 and a GF Value™ of ₹227.84 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Marksans Pharma's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Marksans Pharma  (BOM:524404) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Marksans Pharma Research & Development Related Terms

Marksans Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Marksans Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marksans Pharma Research & Development Chart

Marksans Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Marksans Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524404
85GF Score
Marksans Pharma Ltd BOM:524404
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marksans Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Marksans Pharma (BOM:524404) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Marksans Pharma and its competitors.
Is Marksans Pharma's Research & Development too high?
Marksans Pharma's current Research & Development is ₹0 Mil. Overall, Marksans Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Research & Development compare to LLY and JNJ?
Marksans Pharma's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Marksans Pharma and its competitors. Marksans Pharma's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹227.84, compared to a current price of ₹267.05 — trading 17.2% above its estimated fair value. The current Research & Development is ₹0 Mil. Marksans Pharma's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marksans Pharma (BOM:524404) Overvalued in 2026?

Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued. The current stock price of ₹267.05 is trading 17.2% above its estimated GF Value™ of ₹227.84. GuruFocus considers Marksans Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524404:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹227.84 vs. price of ₹267.05 (17.2% above fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marksans Pharma Business Description

Other Exchanges MARKSANS:India
Address Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
85GF Score

Get the complete analysis for BOM:524404

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹267.05
Price
₹227.84
GF Value